Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma.
Journal: Frontiers in oncology
Published: November 14, 2022
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.
Journal: Investigational new drugs
Published: March 28, 2022
A Primary Care Provider's Guide to Clinical Needs of Women With Spinal Cord Injury.
Journal: Topics in spinal cord injury rehabilitation
Published: November 16, 2020
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
Journal: Oncotarget
Published: February 29, 2016
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 20, 2014
The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 14, 2013
Showing 1-7 of 7
Last Updated: 09/26/2026